DEA Telehealth Prescribing in 2026: What PMHNPs Must Know

Listen to an in-depth podcast of this post

DEA telehealth prescribing PMHNP overview: two hosts break down the full article — no reading required.

For new and early-career PMHNPs navigating DEA telehealth prescribing PMHNP, here is what matters now: The clock is ticking on one of the most consequential regulatory deadlines in psychiatric telehealth. On December 31, 2026, the DEA’s fourth temporary extension of pandemic-era telehealth prescribing flexibilities is set to expire — and permanent rules remain unfinished.

For PMHNPs who prescribe Schedule II–V controlled substances via telehealth, the next eight months demand strategic preparation.

Roughly 137 million Americans live in designated mental health professional shortage areas. Telehealth has been the bridge connecting those patients to psychiatric care. But the regulatory scaffolding holding that bridge together was never meant to be permanent — and the transition to lasting rules will reshape how PMHNPs practice.

“This isn’t just a policy issue — it’s a patient access issue. PMHNPs who built telehealth-forward practices during the pandemic need to understand exactly what’s changing, what’s staying, and what they should be doing right now to protect their patients and their licenses.”

— Lindsay Hill, DNP, PMHNP-BC

What the Current DEA Flexibilities Actually Allow

In the context of DEA telehealth prescribing PMHNP, Under the fourth temporary extension (effective January 1 through December 31, 2026), DEA-registered practitioners can prescribe Schedule II–V controlled substances via interactive audio-video telehealth without ever conducting an in-person evaluation. This applies to both new and existing patients.

For opioid use disorder treatment specifically, audio-only telehealth is permitted for Schedule III–V narcotic medications, including buprenorphine. A separate final rule addressing buprenorphine prescribing took effect December 31, 2025, and operates independently of the broader extension.

In practical terms, this means a PMHNP can evaluate a new patient via video and prescribe stimulants for ADHD, benzodiazepines for anxiety disorders, or buprenorphine for opioid use disorder — all without requiring the patient to show up in person first.

The AANP advocated for this extension as part of the Alliance for Connected Care coalition after the DEA acknowledged receiving numerous communications from patients and providers warning that expiration could abruptly limit access to care.

DEA telehealth prescribing PMHNP: The Proposed Special Registration: What’s Coming Next

In the context of DEA telehealth prescribing PMHNP, The DEA published a proposed rule in January 2025 that would create three special registrations establishing permanent pathways for telehealth prescribing of controlled substances. While the permanent framework hasn’t been finalized, the proposed structure offers the clearest signal of where regulations are heading.

One significant proposed change: prescribers using telehealth to write Schedule II prescriptions would be limited to issuing no more than half of those prescriptions via telehealth. The other half would require an in-person appointment. For PMHNPs running telehealth-only practices who regularly prescribe stimulants, this could mean a fundamental restructuring of their care delivery model.

The special registration would also establish specific documentation, identity verification, and informed consent requirements beyond what most state boards currently mandate for telehealth encounters. Practitioners would need to verify patient identity through government-issued identification and maintain records documenting the clinical rationale for telehealth delivery versus in-person care.

How This Specifically Impacts PMHNP Practice

In the context of DEA telehealth prescribing PMHNP, The impact lands differently depending on your practice model. PMHNPs in brick-and-mortar settings who supplement with telehealth visits face relatively minor adjustments. The bigger disruption hits telehealth-first and telehealth-only practices.

Consider the numbers: a PMHNP who manages 200 active patients via telehealth and writes 80 Schedule II stimulant prescriptions monthly would need to convert roughly 40 of those encounters to in-person visits under the proposed rules. That’s not just a scheduling headache — it’s a potential revenue model overhaul requiring physical office space, support staff, and geographic practice limitations.

State-level variability adds another layer. While the DEA extension is federal, individual state boards of nursing and pharmacy may impose additional restrictions on telehealth prescribing. PMHNPs practicing across state lines — particularly those leveraging the APRN Compact, which is now just two states away from activation — need to track both federal and state requirements simultaneously.

The bottom line: even if the permanent rules adopt some version of the current flexibilities, they will almost certainly include new compliance requirements that don’t exist today.

What Most People Get Wrong About the DEA Extension

The most dangerous assumption is that another extension will just happen. Four consecutive temporary extensions have created a false sense of permanence. But regulatory fatigue is real, and the political pressure to finalize permanent rules increases with every extension.

Many PMHNPs also misunderstand what the current flexibilities actually protect them from. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 — the law that governs online prescribing of controlled substances — requires at least one in-person medical evaluation before a practitioner can prescribe controlled substances via telemedicine. The pandemic-era waivers suspended this requirement. When the waivers end, the Ryan Haight Act’s in-person requirement snaps back unless permanent rules create an alternative pathway.

Another common misconception: the belief that state-level telehealth laws override federal DEA requirements. They don’t. A PMHNP must comply with both. Even if your state permits full-practice authority and unrestricted telehealth prescribing, you still need to satisfy federal controlled substance requirements.

“I talk to new PMHNPs every week who assume telehealth prescribing is just the way things work now. They didn’t practice before the pandemic waivers, so they’ve never known anything different. Understanding the regulatory history isn’t optional — it’s essential for protecting your practice.”

— Lindsay Hill, DNP, PMHNP-BC

How to Prepare Your Practice Before December 31

Strategic preparation now prevents reactive scrambling later. Start with a controlled substance audit: identify every patient who receives Schedule II–V medications exclusively through telehealth and categorize them by schedule and prescription frequency.

Build an in-person transition protocol for your highest-risk prescriptions. If the proposed 50% rule for Schedule II medications becomes final, having an established workflow for converting telehealth visits to hybrid or in-person encounters will give you a significant head start.

Review your documentation practices. The proposed special registration emphasizes identity verification, informed consent specific to telehealth delivery, and clinical justification for remote prescribing. Ensure your current documentation meets or exceeds these anticipated standards.

Finally, monitor the regulatory timeline actively. The DEA is expected to issue permanent rules before the current extension expires. Subscribe to updates from the AANP, your state board of nursing, and the DEA’s Federal Register notices. Join professional networks where regulatory changes are discussed in real time.

The Bottom Line

The 2026 DEA telehealth extension gives PMHNPs a finite window to prescribe controlled substances via telehealth under the most permissive federal framework that has ever existed. Permanent rules will arrive — and they will be more restrictive. The PMHNPs who audit their prescribing patterns, build hybrid practice capabilities, and stay ahead of regulatory changes now will be the ones who maintain uninterrupted patient care when the transition happens.

This content is for educational purposes and does not replace individualized clinical judgment or supervision.